Набір для внутрішньопорожнинної гіпотермії HyperTiss для лікування раку сечового міхура

Передова медична система, призначена для доставки контрольованої гіпотермії безпосередньо в порожнину сечового міхура, що покращує терапевтичні результати лікування раку сечового міхура, підвищуючи чутливість пухлини до хіміотерапії та знижуючи частоту рецидивів.

У "The HyperTiss Intracavitary Hypothermia Set offers a multifactorial approach to bladder tumor management by combining chemotherapy with targeted hyperthermia in a controlled, patient-friendly delivery system. Through a specialized Three-Way Foley Silicone Catheter and advanced temperature control technology, HyperTiss ensures precise thermal and drug regulation—optimizing chemo-hyperthermia’s efficacy against cancerous tissue within the bladder while prioritizing patient safety and comfort.

System Components & Design

Three-Way Foley Silicone Catheter
  • High-Quality Silicone: Minimizes irritation to the bladder wall, promoting patient tolerance during extended intravesical therapy.
  • Multi-Port Access: Enables drug instillation, temperature monitoring, and continuous fluid exchange with minimal instrumentation.
  • Secure Fluid Pathways: Prevents leakage or accidental disconnection, providing stable infusion and drainage ports for the anticancer solution.
  • Two-Way Stopcock: Offers operator-friendly toggling between infusion, drainage, or sealed modes during the procedure.
  • Precise Temperature Regulation: Monitors and maintains fluid temperature within a 41–44°C range (±0.2°C) per physician protocol.
  • Optimized Hyperthermia Delivery: Ensures uniform heat distribution across the bladder mucosa, enhancing drug uptake.
  • Fluid Management: Simplifies infusion, drainage, or recirculation processes for delivering heated chemotherapy solutions.
  • Transparent & Latex-Free: Allows clinicians to observe fluid levels and flow conditions, supporting safe handling.
  • Flexible, Atraumatic: Minimizes mechanical stress on the bladder or the infusion line, enhancing patient safety and comfort.
  • Biocompatible Construction: Resists kinking and maintains consistent fluid passage even under repeated bending.

Therapeutic Rationale: Chemo-Hyperthermia

Synchronized Temperature & Drug Delivery
  • HypertISS: (Hypothermia might be a mis-labelling or it’s “HyperTiss” but anyway) By raising local tissue temperature to 41–44°C, the synergy between heat and chemotherapeutic solutions intensifies cancer cell death.
  • Favorable Tissue Response: Hyperthermia triggers changes in tumor vasculature, enhancing chemotherapeutic penetration and susceptibility of malignant cells to cytotoxic agents.
  • Improved Oncologic Control: Enhanced tissue drug levels plus disruption of tumor cell defense mechanisms can lower progression or relapse of bladder tumors.
  • Better Resource Allocation: Effective local therapy can lessen the need for extensive systemic treatments, cutting down cost and toxicity profiles.

Clinical Advantages & Indications

Enhancing Chemotherapy Efficacy
  • Targeted Hyperthermia: Elevates local temperature in the bladder to potentiate chemotherapeutic effects, thereby improving tumor cell kill rates.
  • Increased Drug Penetration: Heated environment encourages deeper and more consistent uptake of anticancer agents.
  • Combination of Heat & Ionized Molecule Delivery: Creates a synergy that overcomes drug resistance and fosters thorough coverage of bladder lesions.
  • Reduced Systemic Toxicity: Local administration confines drug exposure mainly to the bladder region, potentially lowering systemic side effects.
  • Outpatient/Local Anesthesia: Many procedures can be performed on a short-stay basis, optimizing hospital resources and improving patient quality of life.
  • Reliable Monitoring & Control: Comprehensive alarm systems plus real-time temperature feedback maintain high standards of safety.
  • Automatic Safety Shutdown: Mitigates risk if unexpected temperature or pressure fluctuations occur.
  • Alarm Alerts: Minimizes operator error and ensures the procedure remains within the safe therapeutic window.